Skip to Content

Robert L. Coleman, M.D., FACOG, FACS

Present Title & Affiliation

Primary Appointment

Professor, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
Deputy Chair, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Vice Chair, Clinical Research, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Coleman was recruited back to the MD Anderson faculty in 2004 to help expand and coordinate the Department of Gynecologic Oncology clinical therapeutics program. Finishing the institutionís Gynecologic Oncology fellowship in 1993, he has distinguished himself as a key opinion leader in cancers of the female genital tract. He has authored and co-authored over 400 scientific publications, including over 130 peer-reviewed articles, numerous book chapters, monographs, invited articles and textbooks including, The Handbook of Gynecologic Oncology, Clinical Lymphatic Mapping in Gynecologic Cancers, Prognostic and Predictive Factors in Gynecological Cancers, and most recently, An Atlas of Gynecologic Oncology. He is a frequently invited lecturer for national and international conferences and meetings where he continues to foster global scientific collaboration.

Before returning to MD Anderson, Dr. Coleman served as Division Director of Gynecologic Oncology at Creighton University School of Medicine and Vice-Chairman of Obstetrics and Gynecology at The University of Texas Southwestern Medical Center in Dallas. There he held the inaugural Patricia Duniven-Fletcher Professorship of Gynecologic Oncology. Dr. Colemanís research interests include novel therapeutics for ovarian, uterine and cervical cancer, clinical trial development and statistical design, surgical innovations and graduate education. In partnership with Departmental faculty, he has established a translational medicine pipeline, which fosters, facilitates and vets promising compounds and treatment strategies from preclinical to clinical investigation. He is the institutionís Gynecologic Oncology Group (GOG) Principal Investigator (PI) and is PI or Co-PI for several GOG prospective clinical trials including a national, multicenter, randomized trial evaluating chemotherapy and surgery for recurrent ovarian cancer, as well as, numerous investigator-initiated clinical studies of novel chemotherapeutic and biological compounds in cancers of the ovary, cervix and uterus. He has also been involved in three trials evaluating lymphatic mapping for gynecologic malignancies. He currently is a co-Project leader for the MDACC Ovarian SPORE, the MDACC Uterine SPORE, The Ovarian Cancer Research Fund, and the Marcus Foundation, each of which is sponsoring novel therapeutics trials in gynecologic cancers. In addition, recent funding from the Cancer Prevention Research Institute of Texas (CPRIT) will be used to support a first-in-human therapeutics study of systemically delivered siRNAs in patients with solid tumors.

Dr. Coleman currently serves on the Editorial Board of several peer-reviewed scientific publications. He is an active member of many national organizations including the Society of Gynecologic Oncology, the American College of Surgeons, American Association for Cancer Research and the American Society of Clinical Oncology. He also serves several International Organizations, such as the International Gynecologic Cancer Society, European Society of Gynecologic Oncology and the European Society of Medical Oncology. Dr. Coleman serves as the vice-chairman of the Department of Gynecologic Oncology Clinical Research, Director of Developmental Therapeutics and Research Administration Committees, is a member of the Blanton-Davis Ovarian Cancer Research Program Executive Committee and is a Member of the Board for the Foundation for Womenís Cancer.  In June 2010 he was appointed to the Ann Rife Cox Chair in Gynecology and is a member of the M.D. Anderson Cancer Center's Center for RNA Interference and Non-Coding RNA.        

Office Address

The University of Texas MD Anderson Cancer Center
1155 Herman Pressler Drive
Unit Number: 1362
Houston, TX 77030
Room Number: CPB6.3244
Fax: (713) 792-7586

Education & Training

Degree-Granting Education

1987 Creighton University School of Medicine, Omaha, NE, MD, Medicine
1983 Creighton University, Omaha, NE, BS, Mathematics

Postgraduate Training

7/1991-7/1993 Fellowship, Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, J. Taylor Wharton, M.D.
7/1987-7/1991 Residency, Obstetrics and Gynecology, Northwestern University Medical Center, Chicago, IL, Jack Sciarra, M.D.

Board Certifications

1/1996 American Board of Obstetrics and Gynecology, Division of Gynecologic Oncology
1/1994 American Board of Obstetrics and Gynecology
1/1987 National Board of Medical Examiners


Academic Appointments

Associate Professor, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX, 7/2004-8/2006
Associate Professor, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, 9/2000-7/2004
Assistant Professor, Obstetrics & Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, 9/1996-8/2000
Assistant Professor, Obstetrics and Gynecology, Creighton University School of Medicine, Omaha, NE, 7/1993-8/1996

Other Appointments/Responsibilities

Member, The University of Texas MD Anderson Cancer Center, Center for RNA Interference and Non-Coding RNA, Houston, TX, 2009-present
Member, Board of Directors, Gynecologic Cancer Foundation, Chicago, IL, 3/2006-present
Director, Department of Obstetrics & Gynecology, Creighton University School of Medicine, Omaha, NE, 7/1993-6/1996

Endowed Positions

Patricia Duniven Fletcher Professor in Gynecologic Oncology, Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, 2/2001-7/2004

Institutional Committee Activities

Member, M. D. Anderson Conflict of Interest Committee, 9/2006-9/2011

Honors and Awards

2011 2011 Margaret Greenfield/Carmel Cohen, MD, Excellence in Ovarian Cancer Research Prize, Gynecologic Cancer Foundation

Professional Memberships

American Association for Cancer Research (AACR)
Member, 2000-present
American Association of Cancer Researchers
Member, 1999-present
American Board of Obstetrics and Gynecology (ABOG)
Member, Division of Gynecologic Oncology, 2008-present
Examiner, Division of Gynecologic Oncology, 2006-present
Examiner, 2001-present
American College of Obstetricians and Gynecologists (ACOG)
Fellow, 1994-present
American College of Radiology Imaging Network (ACRIN), Philadelphia, PA
Member, Gynecologic Committee, 2/2010-present
American College of Surgeons (ACS),
Fellow, 1997-present
American Gynecological & Obstetrical Society (AGOS), Washington, DC
Fellow, 2007-present
American Society of Clinical Oncology (ASCO)
Member, Grants Selection Committee, 2006-present
Member, 1997-present
Association of Professors of Gynecology and Obstetrics (APGO)
Member, 1994-present
Felix Rutledge Society
Program Chairman, 2003
Member, 1993-present
Gynecologic Oncology Group (GOG)
Member, Developmental Therapeutics Committee, 12/2005-present
Institutional Principal Investigator, 8/2005-present
Institutional Co-Principal Investigator, 7/2004-8/2005
Member, Ovarian Committee, 11/2000-present
Institutional Co-Principal Investigator, 1/1990-7/2004
Gynecological Cancer Foundation
Member, Board of Directors, 2006-present
Faculty, Ovarian Cancer Survivors Courses, 2005-present
Member, Membership Committee, 1997-present
International Gynecologic Cancer Society (IGCS)
Member, IGCS 12th Annual Scientific Program Committee, 2008
Member, 2002-present
Society of Gynecologic Oncologists (SGO)
Member, Education Committee, 3/2010-3/2014
Member, Program Committee, 2006-2010
Member, Membership Committee, 1998-present
Western Association of Gynecologic Oncologists (WAGO)
Member, 1998-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecol Oncol 122(1):111-5, 7/2011. e-Pub 4/15/2011. PMCID: PMC3104117.
2. Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, Degeest K, Yamada SD, Waggoner S, Coleman RL, Walker JL, Mannel RS. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 121(2):264-8, 5/1/2011. e-Pub 2/1/2011. PMCID: PMC3081997.
3. Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, Coleman RL, Miller BE, Rose PG, Lankes HA. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study. Gynecol Oncol 121(2):303-8, 5/1/2011. e-Pub 2/16/2011. PMCID: PMC3081894.
4. Lacour RA, Euscher E, Atkinson EN, Sun CC, Ramirez PT, Coleman RL, Brown J, Gano JB, Burke TW, Ramondetta LM. A Phase II Trial of Paclitaxel and Carboplatin in Women With Advanced or Recurrent Uterine Carcinosarcoma. Int J Gynecol Cancer 21(3):517-22, 4/2011. PMID: 21436700.
5. Slomovitz BM, Worley MJ, Markman M, Coleman RL. Emerging therapeutics for primary peritoneal cancer. Expert Opin Emerg Drugs 16(1):71-84, 3/2011. PMID: 21352070.
6. Ito K, Tsubamoto H, Itani Y, Kuroboshi H, Fujita H, Nobunaga T, Coleman RL. A feasibility study of carboplatin and weekly paclitaxel combination chemotherapy in endometrial cancer: A Kansai Clinical Oncology Group study (KCOG0015 trial). Gynecol Oncol 120(2):193-7, 2/2011. e-Pub 12/22/2010. PMID: 21075434.
7. Milam MR, Tao X, Coleman RL, Harrell R, Bassett R, Dos Reis R, Ramirez PT. Neoadjuvant Chemotherapy is Associated with Prolonged Primary Treatment Intervals in Patients with Advanced Epithelial Ovarian Cancer. Int J Gynecol Cancer 21(1):66-71, 1/2011. PMID: 21178571.
8. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11(1):59-67, 1/2011. e-Pub 12/16/2010. PMCID: PMC3199132.
9. Carroll AR, Coleman RL, Sood AK. Therapeutic advances in women's cancers. Front Biosci (Schol Ed) 3:82-97, 2011. e-Pub 1/1/2011. PMCID: PMC3199127.
10. Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, Walker C, Ramondetta LM, Burke TW, Gershenson DM, Wolf J. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116(23):5415-9, 12/1/2010. e-Pub 8/2/2010. PMID: 20681032.
11. Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer. Mol Cancer Ther 9(12):3186-99, 12/2010. e-Pub 10/1/2010. PMCID: PMC3005138.
12. Brown J, Smith JA, Ramondetta LM, Sood AK, Ramirez PT, Coleman RL, Levenback CF, Munsell MF, Jung M, Wolf JK. Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer 116(21):4973-9, 11/1/2010. e-Pub 7/21/2010. PMCID: PMC4210375.
13. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK. Regulation of tumor angiogenesis by EZH2. Cancer Cell 18(2):185-97, 8/9/2010. PMCID: PMC2923653.
14. Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther 9(8):2377-88, 8/2010. e-Pub 8/3/2010. PMCID: PMC2933364.
15. Herzog TJ, Krivak TC, Fader AN, Coleman RL. Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Am J Obstet Gynecol 203(1):68.e1-6, 7/2010. e-Pub 3/12/2010. PMID: 20227055.
16. Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, Lu K, Xiao L, Kurzrock R. Phase I clinical trials in 85 patients with gynecologic cancer: The M. D. Anderson Cancer Center experience. Gynecol Oncol 117(3):467-72, 6/2010. e-Pub 3/26/2010. PMCID: PMC2882061.
17. Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM, Han HD, Shahzad MM, Kim HS, Mangala LS, Jennings NB, Mao S, Gooya J, Jackson D, Coleman RL, Sood AK. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res 16(9):2562-70, 5/1/2010. e-Pub 4/13/2010. PMCID: PMC3955167.
18. Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol 11(5):465-75, 5/2010. e-Pub 3/10/2010. PMCID: PMC3199129.
19. Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AK. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer 116(8):1918-25, 4/15/2010. e-Pub 2/17/2010. PMCID: PMC2854845.
20. Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AK. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther 9(4):985-95, 4/2010. e-Pub 4/6/2010. PMCID: PMC2852465.
21. Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther 10(3):431-7, 3/2010. e-Pub 1/2010. PMID: 20092424.
22. Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther 9(3):176-82, 2/2010. e-Pub 2/16/2010. PMCID: PMC3155813.
23. Monk BJ, Coleman RL. Changing the Paradigm in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer From Platinum Doublets to Nonplatinum Doublets and Adding Antiangiogenesis Compounds. Int J Gynecol Cancer 19 Suppl 2:S63-7, 12/2009. PMID: 19955917.
24. Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Tice DA, Sood AK. Combined anti-angiogenic therapy against VEGF and integrin alpha(V)beta(3) in an orthotopic model of ovarian cancer. Cancer Biol Ther 8(23):2263-72, 12/2009. e-Pub 12/19/2009. PMID: 19829059.
25. Coleman RL. Emergence of truly "individualized" therapy: the poly (adenosine diphosphate-ribose) polymerase inhibitors. Curr Oncol Rep 11(6):414-6, 11/2009. PMID: 19840517.
26. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 374(9698):1371-82, 10/2009. e-Pub 9/2009. PMID: 19793610.
27. Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK. EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma. J Natl Cancer Inst 101(17):1193-205, 9/2/2009. e-Pub 7/29/2009. PMCID: PMC2736292.
28. Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Milojevic L, Gershenson DM, Brown J. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol 114(3):431-6, 9/2009. e-Pub 6/13/2009. PMID: 19524286.
29. Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther 8(16):1596-603, 8/2009. e-Pub 8/13/2009. PMID: 19738426.
30. Levenback CF, van der Zee AG, Rob L, Plante M, Covens A, Schneider A, Coleman R, Solima E, Hertel H, Barranger E, Obermair A, Roy M. Sentinel lymph node biopsy in patients with gynecologic cancers Expert panel statement from the International Sentinel Node Society Meeting, February 21, 2008. Gynecol Oncol 114(2):151-6, 8/2009. PMID: 19457548.
31. Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin YG, Edwards C, Broaddus R, Coleman RL, Sood AK. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer 115(12):2684-92, 6/15/2009. e-Pub 4/24/2009. PMID: 19396818.
32. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res 15(11):3770-80, 6/1/2009. e-Pub 5/26/2009. PMCID: PMC2752981.
33. Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK. Dual Targeting of EphA2 and FAK in Ovarian Carcinoma. Cancer Biol Ther 8(11):1123-30, 6/2009. e-Pub 6/24/2009. PMCID: PMC2748749.
34. Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer 124(5):1045-1053, 3/1/2009. e-Pub 9/2008. PMCID: PMC2668132.
35. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer. N Engl J Med 359(25):2641-2650, 12/18/2008. PMCID: PMC2710981.
36. Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res 14(17):5437-46, 9/1/2008. PMCID: PMC2766914.
37. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 68(14):5849-58, 7/15/2008. PMCID: PMC2547344.
38. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 5(4):194-204, 4/2008. e-Pub 2/2008. PMID: 18268546.
39. Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK. Impact of vessel maturation on anti-angiogenic therapy in ovarian cancer. Am J Obstet Gynecol 198(4):477.e1-9, 4/2008. PMCID: PMC2346589.
40. Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, Nugent E, Han LY, Landen CN, Spannuth WA, Lu C, Coleman RL, Gershenson DM, Sood AK. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 13(24):7487-95, 12/2007. PMID: 18094433.
41. Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, Lin YG, Merritt WM, Jennings N, Spannuth WA, Langley R, Gershenson DM, Coleman RL, Kundra V, Sood AK. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res 67(19):9337-45, 10/2007. PMID: 17909042.
42. Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, Spannuth W, Arumugam T, Han LY, Jennings NB, Logsdon C, Jaffe RB, Coleman RL, Sood AK. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 13(14):4209-17, 7/2007. PMID: 17634550.
43. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, Sood AK. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 67(4):1757-68, 2/2007. PMID: 17308118.
44. Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK. Intraperitoneal Delivery of Liposomal siRNA for Therapy of Advanced Ovarian Cancer. Cancer Biol Ther 5:1708-13, 12/2006. PMID: 17106249.
45. Han LY, Landen CN, Trevino JG, Halder J, Lin YG, Kamat AA, Kim TJ, Merritt WM, Coleman RL, Gershenson DM, Shakespeare WC, Wang Y, Sundaramoorth R, Metcalf CA, 3rd, Dalgarno DC, Sawyer TK, Gallick GE, Sood AK. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res 66(17):8633-9, 9/2006. PMID: 16951177.
46. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12(8):939-44, 8/2006. PMID: 16862152.
47. Halder J, Kamat AA, Landen CN, Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 12(16):4916-24, 8/2006. PMID: 16914580.

Book Chapters

1. Alpa M. Nick, Robert L. Coleman, and Anil K. Sood. Molecular therapeutics in epithelial ovarian cancer. In: Ovarian Cancer: State of the Art, 1. Ed(s) Robert C. Bast, Jr. and Maurie Markman. Remedica: London, UK, 109-160, 2009. ISBN: 978-1-905721-53-5.
2. Coleman RL, Moroney JW. Novel Biologic and Cytotoxic Chemotherapeutics in Epithelial Ovarian Cancer. In: Textbook in Gynaecologıcal Oncology. Ed(s) Ali Ayhan, Murat Gultekın, Polat Dursun. Gunes Publishing: Ankara, Turkey, 359-367, 2009. ISBN: 978-975-277-267-0.
3. Ramirez PT, Levenback C, Coleman RL. Laparoscopic Sentinel Lymph Node Identification in Cervical Cancer. In: Nezhat's Operative Gynecologic Laparoscopy and Hysteroscopy, Third. Ed(s) Camran Nezhat, Farr Nezhat, Ceana Nezhat. Cambridge University Press: New York, 447-452, 2008.
4. Han LY, Coleman RL. Ovarian Cancer Staging. In: Gynecologic Procedures for the General Surgeon, Operative Techniques in General Surgery. 9, Issue 2. Ed(s) Koltun WA. Elsevier: Philadelphia, 51-91, 2007.
5. Rao GG Coleman RL. Fallopian tube cancer. In: Gynecology & Obstetrics. JB Lippincott, 2004.
6. Herzog TJ, Kost ER, Coleman RL. Gynecology. In: Laparoscopic Surgery: Principles and Procedures. Marcel Dekker, Inc, 2004.
7. Coleman RL Coleman FK. Radiotherapy in vulvar carcinoma. In: Gynecology & Obstetrics. JB Lippincott, 2004.
8. Coleman RL, Munkarah A, Bristow RE. Secondary cytoreductive surgery. In print. In: Surgery for Ovarian Cancer: Principles and Practice. Parthenon Publishing Group Limited, 2004.
9. Coleman RL. Lymphatic mapping. In: An Atlas of Gynecologic Oncology. Taylor & Francis Books, Ltd, 2003.
10. Coleman RL. Secondary cytoreduction surgery for ovarian cancer. In Production. In: Principles and Practice. Parthenon Publishing, 2003.
11. Coleman RL. Anatomy and natural history of invasive female lower genital tract cancers (FLGTCs): Carcinomas of the cervix, vagina, and vulva. In: Atlas of Clinical Oncology. B.C. Decker Inc, 47-62, 2001.
12. Coleman RL Santoso JT. Vulvar carcinoma. In: Current Treatment Options in Oncology. 1(2). Current Science, Inc, 177-190, 2000.
13. Coleman RL Coleman FK. Radiotherapy in epithelial ovarian cancer. In: Gynecology & Obstetrics. 4:37. Williams & Wilkins/JB Lippincott, 1-15, 1999.
14. Coleman RL. Fallopian tube carcinoma. In: Gynecology & Obstetrics. 4:36. JB Lippincott, 1-90, 1998.
15. Hallum AV, Coleman RL, Wolf J. Gynecologic oncology. In: The M. D. Anderson Surgical Oncology Handbook. Little, Brown and Co, 326-368, 1995.
16. Coleman RL. The retroperitoneal mass. In: Management of Complications in Gynecologic Surgery. WB Saunders Company, 115-126, 1995.

Books (edited and written)

1. Lee P. Shulman, M.D. Ed(s) Lee P. Schulman, M.D. 2007 Year Book of Obstetrics, Gynecology, and Women's Health. In: 2007 Year Book Series. Elsevier: Philadelphia, PA, 2007.
2. Levenback, C, Coleman RL, Lu K, Sood AK. Ed(s) Levenback, C, Coleman RL, Lu K, Sood AK. Prognostic and Predictive Factors in Gynecologic Cancers, 1. Informa UK Ltd. London, 2007. ISBN: 0415391725.
3. Levenback C, Coleman R, Van der Zee AGJ. Clinical Lymphatic Mapping in Gynecologic Cancers. Martin Dunitz Ltd, 2004.
4. Santoso JT Coleman RL. Handbook of Gyn Oncology. McGraw-Hill, 2001.
5. Gershenson DM (ed) Coleman RL (guest ed). Operative Techniques in Gynecologic Surgery. WB Saunders Company, 2001.
6. Hallum AV, Coleman RL, Segreti E. Epithelial ovarian cancer. In: Study Guide for Textbook of Gynecology. WB Saunders Company, 1994.

Grant & Contract Support

Title: EphA2 Targeting in Uterine Cancer
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 3/1/2010 - 2/28/2014

Last updated: 6/30/2015